Lilly's (LLY) Risk/Reward Looks Good Ahead of Q3 Report - BMO

Eli Lilly & Co. (LLY) Declares $0.50 Quarterly Dividend; 2.5% Yield

Eli Lilly & Co. (NYSE: LLY) declared a quarterly dividend of $0.50 per share, or $2 annualized.

The dividend will be payable on December 10, 2015, to stockholders of record on November 13, 2015, with an ex-dividend date of November 10, 2015.

The annual yield on the dividend is 2.5... More

Eli Lilly & Co. (LLY), Boehringer Announces U.S. Availability of Synjardy Tabs

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) announced that Synjardy® (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States. The U.S. Food and Drug Administration (FDA) approved SYNJARDY at the end of August as an adjunct to diet and exercise to improve glycemic control in adults with T2D who are not adequately controlled on a regimen containing empagliflozin or metformin alone, or in patients... More

Eli Lilly (LLY), Incyte (INCY) Announced Baricitinib Demonstrates Superiority to Adalimumab in Phase 3 RA Study

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.

The study met its primary objective of demonstrating superiority compared to placebo after 12 weeks of treatment based on ACR20 response a standard clinical measure that represents at least a 20 percent improvement in RA disease activity. Baricitinib was also superior to adalimumab on key secondary objectives of ACR20 response and improvement in DAS28-hsCRP score... More